KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), has begun recruitment for its Phase 2 clinical trial of the Company’s lead oncology agent PV-10 at the M.D. Anderson Cancer Center, in Houston, TX (http://www.mdanderson.org). Professor Merrick Ross, MD, is the lead investigator of the team at M.D. Anderson. This first U.S. center joins those already announced in Sydney and Brisbane, Australia. Over the next several months, the Company expects to continue expansion of the study to include sites in most major population centers in Australia as well as several additional sites in the United States.
